<DOC>
	<DOCNO>NCT01136174</DOCNO>
	<brief_summary>To investigate safety BIBF 1120 Japanese patient idiopathic pulmonary fibrosis ( IPF ) , without pirfenidone background treatment . To assess pharmacokinetics BIBF 1120 Japanese patient , without pirfenidone background treatment . To assess pharmacokinetics pirfenidone Japanese patient , alone combination BIBF 1120 treatment .</brief_summary>
	<brief_title>Safety PK Study BIBF 1120 Japanese Patients With IPF</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis idiopathic pulmonary fibrosis ( IPF ) accord American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) guideline 2 . Forced vital capacity ( FVC ) 5090 % 3 . Diffusing capacity carbon monoxide ( DLCO ) 3079 % 4 . For patient pirfenidone , steady dose least 3 month Exclusion criterion : 1 . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &gt; 1.5 x upper limit normal range ( ULN ) screening . 2 . Bilirubin &gt; 1.5 x ULN screen . 3 . Relevant airways obstruction ( i.e . prebronchodilator FEV1/FVC &lt; 0.7 ) screening . 4 . Continuous oxygen supplementation . 5 . Active infection screen randomisation . 6 . Being treat follow concomitant medication . Oral corticosteroid medication unstable dose ketoconazole atazanavir 7 . Patients expect go lung transplantation , rapidly deteriorate disease , life expectancy le 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>